Clinical trial · Observational
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)
Modulatory Effect of Prodigiosin or Pioglitazone on Tumor Immune Microenvironment and the Crosstalk to Immune-Checkpoint Protein(s)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Lung cancer is one of the most common and serious types of cancer. Lung tumor cells exploit immune checkpoint proteins (ICPs) to maintain immune tolerance and thus promote tumor progression and invasion. Inhibition of ICPs using antibody therapies is one of the most common approaches for the treatment of lung cancer. Unfortunately, these antibody-based therapies can lead to severe adverse events. Moreover, a significant number of patients do not respond to immune checkpoint inhibition due to tumor heterogeneity and the immunosuppressive tumor immune microenvironment (TIME). The use of small molecule targeted approach instead of antagonizing antibodies may have the potential advantage of being able to target multiple ICPs in TIME with a single agent as well as improved tumor distribution.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| NSCLC | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- control
- description
- Healthy volunteers not suffering from any disease or not taking any Medications
- label
- Diseased
- description
- NSCLC patients
Primary outcomes (4)
- measure
- Gene Expression (mRNA levels)
- timeFrame
- 36 months
- description
- mRNA levels of HSP90, IL-6, STAT3,c-MYC and the novel immune checkpoint proteins by qRT-PCR from blood samples collected from NSCLC patients and cell pellets collected from lung cancer cell lines before and after pioglitazone or prodigiosin treatment
- measure
- Gene Expression (Protein levels)
- timeFrame
- 36 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Adults over 50 years old with NSCLC. Exclusion Criteria: * Lung cancer patients with any cancer other than NSCLC * Lung cancer patients with incomplete data or incomplete histopathology diagnosis report.
References
Publications (20)
- BACKGROUNDAbdelhamed S, Ogura K, Yokoyama S, Saiki I, Hayakawa Y. AKT-STAT3 Pathway as a Downstream Target of EGFR Signaling to Regulate PD-L1 Expression on NSCLC cells. J Cancer. 2016 Jul 18;7(12):1579-1586. doi: 10.7150/jca.14713. eCollection 2016. PMID 27698894
- BACKGROUNDAnwar MM, Shalaby M, Embaby AM, Saeed H, Agwa MM, Hussein A. Prodigiosin/PU-H71 as a novel potential combined therapy for triple negative breast cancer (TNBC): preclinical insights. Sci Rep. 2020 Sep 7;10(1):14706. doi: 10.1038/s41598-020-71157-w. PMID 32895397
- BACKGROUNDCasey SC, Baylot V, Felsher DW. MYC: Master Regulator of Immune Privilege. Trends Immunol. 2017 Apr;38(4):298-305. doi: 10.1016/j.it.2017.01.002. Epub 2017 Feb 21. PMID 28233639
- BACKGROUNDFu S, Liu Y, Zhang Z, Mei M, Chen Q, Wang S, Yang X, Sun T, Ma M, Xie W. Identification of a Novel Myc-Regulated Gene Signature for Patients with Kidney Renal Clear Cell Carcinoma. J Oncol. 2022 Dec 26;2022:3487859. doi: 10.1155/2022/3487859. eCollection 2022. PMID 37342680
- BACKGROUNDGao FY, Li XT, Xu K, Wang RT, Guan XX. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023 Jan 31;21(1):28. doi: 10.1186/s12964-023-01043-1. PMID 36721232
- BACKGROUNDGou Q, Che S, Chen M, Chen H, Shi J, Hou Y. PPARgamma inhibited tumor immune escape by inducing PD-L1 autophagic degradation. Cancer Sci. 2023 Jul;114(7):2871-2881. doi: 10.1111/cas.15818. Epub 2023 Apr 24. PMID 37096255
- BACKGROUNDHarada D, Takigawa N, Kiura K. The Role of STAT3 in Non-Small Cell Lung Cancer. Cancers (Basel). 2014 Mar 26;6(2):708-22. doi: 10.3390/cancers6020708. PMID 24675568
- Jia X, Qian J, Chen H, Liu Q, Hussain S, Jin J, Shi J, Hou Y. PPARgamma agonist pioglitazone enhances colorectal cancer immunotherapy by inducing PD-L1 autophagic degradation. Eur J Pharmacol. 2023 Jul 5;950:175749. doi: 10.1016/j.ejphar.2023.175749. Epub 2023 Apr 25.